Long-term efficacy of occlusive therapy with topical pimecrolimus in severe dyshidrosiform hand and foot eczema [2]

Dermatology

Volumn 214, Issue 1, 2006, Pages 99-100

  Schürmeyer Horst, Funda ^a   Luger, Thomas A ^a   Böhm, Markus ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

Dyshidrosiform eczema; Pimecrolimus; Topical therapy

Indexed keywords

CLOBETASOL; COBALT CHLORIDE; DICHROMATE SODIUM; FRAGRANCE; GUANIDINE DERIVATIVE; PHTHALIMIDE DERIVATIVE; PIMECROLIMUS;

AGED; ANAMNESIS; CASE REPORT; CLINICAL FEATURE; DRUG EFFICACY; DYSHIDROSIFORM ECZEMA; ECZEMA; FOOT ECZEMA; HAND ECZEMA; HUMAN; LABORATORY TEST; LETTER; MALE; PRIORITY JOURNAL; PRURITUS; SKIN SENSITIZATION;

ADMINISTRATION, TOPICAL; AGED; BIOPSY; DERMATOLOGIC AGENTS; ECZEMA, DYSHIDROTIC; FOLLOW-UP STUDIES; FOOT; HAND; HUMANS; MALE; OCCLUSIVE DRESSINGS; PEPTIDYLPROLYL ISOMERASE; SEVERITY OF ILLNESS INDEX; TACROLIMUS; TIME FACTORS;

EID: 33845924987     PISSN: 10188665     EISSN: None     Source Type: Journal    
DOI: 10.1159/000096923     Document Type: Letter

References (10)

1. Mrowietz U, Graeber M, Brautigam M, Thurston M, Wagenaar A, Weidinger G, Christophers E: The novel ascomycin derivative SDZ ASM 981 is effective for psoriasis when used topically under occlusion. Br J Dermatol 1998;139:992-996.
2. Kreuter A, Gambichler T, Breuckmann F, Pawlak FM, Stucker M, Ba der A, Altmeyer P, Freitag M: Pimecrolimus 1% cream for cutaneous lupus erythematosus. J Am Acad Dermatol 2004;51:407-410.
3. Böhm M, Bonsmann G, Luger T: Resolution of lichen aureus in a 10-year-old child after topical pimecrolimus. Br J Dermatol 2004;150:519-520.
4. Chu CY: The use of 1% pimecrolimus cream for the treatment of steroid-induced rosacea. Br J Dermatol 2005;152:398-403.
5. Queille-Roussel C, Paul C, Duteil L, Lefebvre MC, Rapatz G, Zagula M, Ortonne JP: The new topical ascomycin derivative SDZ ASM 981 does not induce skin atrophy when applied to normal skin for 4 weeks: a randomized, double-blind controlled study. Br J Dermatol 2001;144:507-513.
6. Wahn U, Bos JD, Goodfield M, Caputo R, Papp K, Manjra A, Dobozy A, Paul C, Molloy S, Hultsch T, Graeber M, Cherill R, de Prost Y; Flare Reduction in Eczema with Elidel (Children) Multicenter Investigator Study Group: Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children. Pediatrics 2002;110:1-8.
7. Meurer M, Fartasch M, Albrecht G, Vogt T, Worm M, Ruzicka T, Altmeyer PJ, Schneider D, Weidinger G, Braeutigam M; CASM-DE-01 Study Group: Long-term efficacy and safety of pimecrolimus cream 1% in adults with moderate atopic dermatitis. Dermatology 2004;208:365-372.
8. Luger TA, Lahfa M, Fölster-Holst R, Gulliver WP, Allen R, Molloy S, Barbier N, Paul C, Bos JD: Long-term safety and tolerability of pimecrolimus cream 1% and topical corticosteroids in adults with moderate to severe atopic dermatitis. J Derm Treat 2004;15:169-178.
9. Thaci D, Steinmeyer K, Ebelin ME, Scott G, Kaufmann R: Occlusive treatment of chronic hand dermatitis with pimecrolimus cream 1% results in low systemic exposure, is well tolerated, safe, and effective. An open study. Dermatology 2003;207:37-42.
10. Belsito DV, Fowler JF Jr, Marks JG Jr, Pariser DM, Hanifin J, Duarte IA, Pires MC, Cruz PD Jr, Langley RG, Patel P, Bush C, Thurston M, Graeber M, Cherill R; Multicenter Investigator Group: Pimecrolimus cream 1%: a potential new treatment for chronic hand dermatitis. Cutis 2004;73:31-38.